TOP ROW FROM LEFT TO RIGHT: Daniel Probert Research Associate, Process Development, Henry Hodge Business Development Associate, Sarah Hale Senior Scientist, Analytical Development, Sarah Sebastian Director, Research and Development, Chris Ellis Chief Operating Officer, Alison Turner Director, Process Development, Dr Tom Evans CEO, Vesa Qarkaxhija Clinical Trials Administrator, Lawrence Petherbridge Research Associate, Molecular Virology, Vicky Wheeler Programme Manager.
BOTTOM ROW FROM LEFT TO RIGHT: Graham Griffiths Chief Business Officer, Stella Ackrell Senior Project Manager, Manufacturing, Frederick Momoh Research Associate, Early Development Lab/Process Development, Jamie Comley Laboratory Technician, Denise McCarron Clinical Trials Administrator, Angela Robinson Research Associate, Analytical Development, Keith Howard Chief Development Officer, Elizabeth Eagling-Vose Head of Clinical Operations, Kinga Piotrowska Research Associate, Early Development Lab/Process Development, Pippa Rathbone Executive Administrator, Louise Bussey Clinical Study Manager.
NOT PRESENT: Bernie Macdonald Head of IP, Dalila Karbiche Clinical Study Manager – Consultant, Barsha Thapa Research Associate, Early Development Lab/Process Development, Sophie Jameson Part-time Research Associate, Process Development, Gwen Tucker Clinical Study Manager, Daniel Jones Senior Scientist, MD Forazi Senior Scientist, Linda Kelly Programme Manager.
Chief Executive Officer
William “Bill” Enright is a seasoned biotech executive with more than thirty years of experience in building and financing both privately held and publicly held companies. Bill spent more than ten years at Altimmune (NASDAQ: ALT) as a Director, President & CEO, moving multiple programs into clinical testing, completing several acquisitions and eventually taking the company public. Prior to joining Altimmune, Bill spent six years with GenVec, Inc. (acquired by Intrexon) with increasing responsibilities, which included a role as Head of Business Development. Bill has raised more than $300 million through private, public and non-dilutive financings.
Bill brings a breadth of experiences in a variety of positions within the life science/biotech industry, including time as a consultant, a bench scientist and 12 years with Life Technologies, Inc. (acquired by Thermo-Fisher), working in various senior level licensing, business management, manufacturing and research roles.
Bill received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University.
CSO & Board Director
Dr. Thomas G. Evans
He established a laboratory during his first position at the University of Utah and directed the HIV clinic. He moved to the University of Rochester as Associate Professor for 5 years, before becoming Infectious Diseases Division Chief and tenured full Professor at the University of California, Davis. His academic research centered on leishmania and HIV vaccine development and led to him joining Vical, a DNA vaccine developer as Chief Medical Officer in 2002. In 2005 he joined the Novartis Institutes for Biomedical Research as Global Head of Infectious Diseases Translational Medicine and Research. In September 2008 he moved to Shanghai as VP for Translational Sciences in Asia for Novartis. In September 2010 he joined Aeras, a non-profit Product Development Partnership with a mission to develop global tuberculosis vaccines, as the Chief Scientific Officer, and became CEO in February 2013. He has over 140 authored publications.
Tom joined Vaccitech in the spring of 2016. Having successfully built Vaccitech to a late clinical stage biopharmaceutical company as CEO, in his role as CSO, Tom focuses more specifically on the science, research and development that underpin Vaccitech’s next generation T-cell induction products.
Chief Medical Officer
Dr Mariem Charafeddine
Mariem Charafeddine received her M.D. from the University of Casablanca, Faculty of Medicine and Pharmacy in Morocco. She is also an alumni of ESCP Europe Business School.
As part of her career in Europe and the USA, she has held several positions in medical affairs, clinical development and pharmacovigilance in multinational pharmaceutical companies. Her areas of expertise include infectious diseases and hepatology.
Mariem joined Vaccitech as Chief Medical Officer on July 15, 2019.
Dr Keith Howard
Professor of Vaccinology
Professor Adrian Hill
Board of Directors
Robin Wright has extensive senior level experience as a CFO of public companies in both the pharmaceutical and biotechnology industries. He is a qualified accountant and currently Chief Financial Officer of the biopharmaceutical company Pharming Group NV in the Netherlands.
Robin joined Pharming from Sweden-based Karolinska Development AB (publ.) (KDEV: SS), where he was CFO and Head of Business Development. Mr. Wright was CFO and Head of Business Development at Orexo AB (publ.) (ORX: SS) in Sweden prior to this. Before going to Sweden, he worked in private equity and corporate finance advisory roles, including long periods at Citibank Salomon Smith Barney and Barclays de Zoete Wedd. He has completed over 170 global license and M&A transactions as well as several hundred financing transactions in debt and equity within the pharma/ biotech sector. Mr. Wright holds a BA degree in Chemistry from Oxford University and is a Fellow of the Institute of Chartered Accountants in England and Wales in the UK.